Address
2355 Westwood Blvd.
Los Angeles, CA 90064
United States of America (the)
Phone
310-948-2356
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1
First IPO Date
September 16, 2024
| Name | Title | Pay | Year Born |
| John S. Yu | Chief Executive Officer, Chairman & Secretary | 287,500 | 1964 |
| Douglas W. Samuelson | Chief Financial Officer | 112,500 | 1960 |
| Ramachandran Murali | Vice President of Research & Development | 127,500 | 1960 |
| Neil A. Bhowmick | Chief Scientific Officer | 156,250 | 1971 |
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.